2.2500 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||2.2500 x 38500|
|Ask||2.2500 x 28000|
|Day's Range||2.2200 - 2.3800|
|52 Week Range||1.9600 - 4.1200|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. The wealth of strategic, operational and legal knowledge she brings to the company will be invaluable as we continue to expand our potential market opportunity," said Raul Rodriguez, president and CEO of Rigel.
Raul Rodriguez has been the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
Fourth quarter total revenues of $37.9 million ; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million ; full year net product sales of $13.9 million Conference call ...
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market ...
NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...
CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is solely dependent on the ability of medical experts and healthcare professionals to work to provide the best quality of care for patients in the space. With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As companies in the healthcare industry work to better understand the needs of their patients, the sector, in its entirety, may boast impressive opportunities for investors looking to the space.
Shares of Rigel Pharmaceuticals Inc. shot up 9% in premarket trade Wednesday after the company announced it had entered a license and supply agreement with Spain-based Grifols, S.A. to commercialize fostamatinib disodium hexahydrate, its treatment for thrombocytopenia in adult patients. It is commercially available in the U.S. under the brand name Tavalisse. Under the terms of the agreement, Rigel will receive a $30 million upfront cash payment, with a potential $297.5 million in payments upon reaching certain regulatory and commercial milestones. That figure includes a potential $20 million payment upon the European Medicines Agency approving fostamatinib for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Rigel will also receive royalty payments based on tiered net sales, which the company said could reach 30% of net sales. In return, Grifols will receive exclusive rights to fostamatinib in Europe and Turkey. However, if fostamatinib has not been approved by the EMA for the treatment of ITP by 2021, Grifols will have the option to terminate the entire agreement, the companies said, and Rigel will have to pay Grifols $25 million to regain all rights to fostamatinib in Europe and Turkey. Rigel shares have fallen 12% in the year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 12.7%. The S&P 500 has gained 5%.
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and Read More...
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today provided a business update, including the quantity of TAVALISSE™ bottles sold in 2018 and its cash position as of December 31, 2018, as well as an overview of its strategy for 2019. The company's president and CEO, Raul Rodriguez, will provide a more detailed company overview during his presentation at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 at 11:00am PT. The ongoing execution of our TAVALISSE commercial strategy will be a key focus in 2019," said Mr. Rodriguez.
SOUTH SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, is scheduled to present a company overview ...
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...
SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's executive vice president and chief financial officer, ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Rigel Pharmaceuticals Inc (NASDAQ:RIGL), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is RIGL Read More...
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel (RIGL) delivered earnings and revenue surprises of 12.50% and 38.41%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?